Glucagonlike peptide1 receptor agonists (GLP1RAs) have emerged as a prominent treatment for T2DM with a notable weight loss effect via delayed gastric emptying, glucagon inhibition and stimulation of central receptors that modulate appetite suppression and energy expenditure [3, 4]
Limited muscle mass reduces energy usage
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Instead of fixating on a single target weight, discuss improvements in energy levels, mobility, disease risk markers like blood pressure and cholesterol, and how you want to feel day-to-day
From your initial consultation to continuous follow-up, we are committed to guiding you through every step of your weight loss journey
Real-World Impact In clinical studies, people taking semaglutide experienced significant weight loss